Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02485054
Other study ID # MOA_2014-32
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 2015
Est. completion date October 2018

Study information

Verified date March 2019
Source Fondation Ophtalmologique Adolphe de Rothschild
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The transient visual disturbances (TVD) are defined by a short abnormality of visual function. Their etiology may be ophthalmological, neurological non-ischemic or of ischemic origin.

The difficulty is to recognize an ischemic mechanism which imposes emergency cares.

A clinical score could help the clinician to recognize the etiology of the TVD .


Recruitment information / eligibility

Status Completed
Enrollment 403
Est. completion date October 2018
Est. primary completion date October 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Transient visual disturbances (i.e. less than 24 hours) during the last 8 days

Exclusion Criteria:

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Clinical, ophthalmological and neurological evaluation
Clinical : questionnaire about the symptoms and about the vascular risk factors Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, blood count, erythrocytes sedimentation rate, C reactive protein, visual field, optical coherence tomography, retinography

Locations

Country Name City State
France Fondation ophtalmologique Adolphe de Rothschild Paris
France Hôpital Bichat Paris

Sponsors (1)

Lead Sponsor Collaborator
Fondation Ophtalmologique Adolphe de Rothschild

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Etiology, ischemic or not, of the initial transient visual disturbance Clinical : questionnaire about the symptoms and about the vascular risk factors Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, blood count, erythrocytes sedimentation rate, C reactive protein, visual field, optical coherence tomography, retinography and a new evaluation after 3 months. 3 months
Secondary Incidence of new visual transient ischemic attacks during the 3 months of follow-up Clinical : questionnaire about the symptoms and about the vascular risk factors Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, blood count, erythrocytes sedimentation rate, C reactive protein, visual field, optical coherence tomography, retinography and a new evaluation after 3 months. 3 months
Secondary Incidence of visual ischemic strokes during the 3 months of follow-up Clinical : questionnaire about the symptoms and about the vascular risk factors Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, blood count, erythrocytes sedimentation rate, C reactive protein, visual field, optical coherence tomography, retinography and a new evaluation after 3 months. 3 months
Secondary Incidence of transient ischemic attacks, visual or not visual, during the 3 months of follow-up Clinical : questionnaire about the symptoms and about the vascular risk factors Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, blood count, erythrocytes sedimentation rate, C reactive protein, visual field, optical coherence tomography, retinography and a new evaluation after 3 months. 3 months
Secondary Incidence of ischemic strokes, visual or not visual, during the 3 months of follow-up Clinical : questionnaire about the symptoms and about the vascular risk factors Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, blood count, erythrocytes sedimentation rate, C reactive protein, visual field, optical coherence tomography, retinography and a new evaluation after 3 months. 3 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03872479 - Single Ascending Dose Study in Participants With LCA10 Phase 1/Phase 2
Active, not recruiting NCT02595502 - Clinical Evaluation of Two Silicone Hydrogel Daily Disposable Contact Lenses N/A
Completed NCT00985231 - Performance Evaluation of Contact Lenses Among a Population of Adapted Contact Lens Wearers N/A
Recruiting NCT05208658 - Characteristics of the Vergence Responses of Binocularly Normal Subjects After a Vision Therapy Protocol N/A
Recruiting NCT06077682 - Cycloplegic Refraction in Pediatric Patients With Esotropia Phase 4
Active, not recruiting NCT04123626 - A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene Phase 1/Phase 2
Recruiting NCT04693247 - Handheld Device Compared With a Standard Eye Care Diagnostic Device in Measuring Ophthalmic Refraction N/A
Completed NCT01318577 - Study of A New Contact Lens Cleaning and Disinfecting Solution N/A
Completed NCT03763721 - The ADVISE Study: Advanced Visualization In Corneal Surgery Evaluation N/A
Completed NCT05602402 - To Evaluate the Efficacy and Safety of CAEP-01 on Eye Strain in Children With Heavy Screen Use N/A
Not yet recruiting NCT06085430 - Kubota Glass Parameter Refinement Study N/A
Completed NCT04347564 - Usability of the Software MacuFix for the Categorization of Metamorphopsia
Completed NCT01546402 - Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema Phase 4
Completed NCT01698788 - Effect of Intraoperative Dexamethasone Implant in Taut Posterior Hyaloid Removal in Diabetic Macular Edema N/A
Completed NCT03169855 - Validation of Mesopic and Photopic Contrast Vision Tests With Respect to Nighttime Driving Ability
Terminated NCT03913130 - Extension Study to Study PQ-110-001 (NCT03140969) Phase 1/Phase 2
Recruiting NCT03479021 - SPOT Vision Screening
Recruiting NCT05600140 - Viewing Strategy Training in Children With (Cerebral) Visual Impairment N/A
Completed NCT03780257 - Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene Phase 1/Phase 2
Recruiting NCT04855045 - An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. Phase 2/Phase 3